Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. reports clinical-stage oncology developments centered on targeted radiopharmaceuticals for solid tumors. The company’s miniprotein radioconjugate platform supports AKY-1189, a Nectin-4 program with potential across urothelial, breast, non-small cell lung, colorectal, cervical, and head and neck cancers, and AKY-2519, a B7-H3 program for prostate, lung, colorectal, and other solid tumors.
Recurring updates include FDA actions such as IND clearances and Fast Track designation, clinical-trial initiations, imaging and dosimetry data presentations, business and financial results, investor-conference participation, and board and committee changes. News also covers Aktis’ collaboration with Eli Lilly and Company to develop radioconjugates outside its proprietary pipeline.
Akoustis Technologies, Inc. reported third-quarter results with a 7% increase in revenue quarter-over-quarter, along with a 13% growth in filter-related revenue. The company anticipates breakeven operating cash flow in the next nine months due to cost-saving initiatives. Akoustis continues to secure design wins in various markets like Wi-Fi, 5G Infrastructure, Automotive, and Defense, projecting robust customer activity and revenue growth.
Akoustis Technologies, Inc. will webcast its Q3FY24 results on May 13 at 8:00 am ET. The company, known for its BAW high-band RF filters, maintains momentum with robust demand, an expanding sales pipeline, and new design wins in target markets like Wi-Fi, 5G Infrastructure, Automotive, and Defense.
Akoustis Technologies, Inc. announced the integration of four high-performance patented XBAW® filters into two new platforms with a Tier-1 Network Infrastructure customer. The filters will be used in Wi-Fi 7 enterprise and home gateway solutions, with production ramp scheduled throughout 2024. Akoustis continues to secure design wins in various target markets, showcasing robust demand for its products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.